– Adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers
– Adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers
– Adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable
– Adult patients with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers
– Adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent
– Adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers
– Adults with active non-radiographic axial spondyloarthritis having objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal Anti-inflammatory drugs (NSAIDs)